Efficacy of gamma knife radiosurgery in brain metastases of primary gynecological tumors
Gynecological brain metastases (BM) are rare and usually develop as part of widespread disseminated disease. Despite treatment, the majority of these patients do not survive > 1 year due to advanced extracranial disease. The use of Gamma Knife Radiosurgery (GKRS) for gynecological BM is not well known. The goal of this study is to evaluate the efficacy of GKRS for gynecological BM.
We performed a retrospective study of patients with gynecological BM who underwent GKRS between 2002 and 2015. A total of 41 patients were included. Outcome measures were local tumor control (LC), development of new BM and/or leptomeningeal disease, overall intracranial progression free survival (PFS) and survival.
LC was 100%, 92%, 80%, 75% and 67% at 3, 6, 9, 12 and 15 months, respectively. PFS was 90%, 61%, 41%, 23% and 13% at 3, 6, 9, 12 and 15 months, respectively. During follow-up (FU), 18 (44%) patients had intracranial progression. Distant BM occurred in 29% of the patients. Local recurrence and distant recurrence occurred after a mean FU time of 15.5 (2.6–71.9) and 11.4 (2–40) months, respectively. Thirty-one (76%) patients died due to extracranial tumor progression and only 2 (5%) patients died due to progressive intracranial disease. The overall mean survival from time of GKRS was 19 months (1–109). The 6-month, 1-year, and 2-year survival rate from the time of GKRS were 71%, 46%, and 22%, respectively.
GKRS is a good treatment option for controlling gynecological BM. As most patients die due to extracranial tumor progression, their survival might improve with better systemic treatment options in addition to GKRS.
KeywordsGynecological tumors Gynecological brain metastases Gamma knife radiosurgery
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
For this type of study formal consent is not required.
- 1.Larson DM, Copeland LJ, Moser RP, Malone JM Jr, Gershenson DM, Wharton JT (1986) Central nervous system metastases in epithelial ovarian carcinoma. Obstet Gynecol 68:746–750Google Scholar
- 2.Kolomainen DF, Larkin JM, Badran M, A’Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME (2002) Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol 20:982–986. https://doi.org/10.1200/jco.2002.20.4.982 CrossRefGoogle Scholar
- 13.Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA (2005) Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res 25:3553–3558Google Scholar
- 15.Sehouli J, Pietzner K, Harter P, Munstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G (2010) Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol 21:2201–2205. https://doi.org/10.1093/annonc/mdq229 CrossRefGoogle Scholar
- 17.De Porre PM, Subandono Tjokrowardojo AJ (1992) Brain metastases of endometrial carcinoma. Case report and review of literature. Strahlentherapie Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 168:100–101Google Scholar
- 21.Ogawa K, Yoshii Y, Aoki Y, Nagai Y, Tsuchida Y, Toita T, Kakinohana Y, Tamaki W, Iraha S, Adachi G, Hirakawa M, Kamiyama K, Inamine M, Hyodo A, Murayama S (2008) Treatment and prognosis of brain metastases from gynecological cancers. Neurologia medico-chirurgica 48:57–62; discussion 62–53CrossRefGoogle Scholar
- 24.Shin HK, Kim JH, Lee do H, Cho YH, Kwon do H, Roh SW (2016) Clinical outcomes of gamma knife radiosurgery for metastatic brain tumors from gynecologic cancer: prognostic factors in local treatment failure and survival. J Korean Neurosurg Soc 59:392–399. https://doi.org/10.3340/jkns.2016.59.4.392 CrossRefGoogle Scholar
- 28.Jawahar A, Matthew RE, Minagar A, Shukla D, Zhang JH, Willis BK, Ampil F, Nanda A (2004) Gamma knife surgery in the management of brain metastases from lung carcinoma: a retrospective analysis of survival, local tumor control, and freedom from new brain metastasis. J Neurosurg 100:842–847. https://doi.org/10.3171/jns.2004.100.5.0842 CrossRefGoogle Scholar
- 30.Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2002) Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97:1276–1281. https://doi.org/10.3171/jns.2002.97.6.1276 CrossRefGoogle Scholar
- 35.Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342–349. https://doi.org/10.3171/jns.2003.98.2.0342 CrossRefGoogle Scholar
- 44.Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. https://doi.org/10.1016/s1470-2045(09)70263-3 CrossRefGoogle Scholar
- 45.Chougule PB, Burton-Williams M, Saris S, Zheng Z, Ponte B, Noren G, Alderson L, Friehs G, Wazer D, Epstein M Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol 48: 114 https://doi.org/10.1016/S0360-3016(00)80024-3
- 46.Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, Regine WF, Weltman E, King VJ, Breneman JC, Sperduto PW, Mehta MP (2002) A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol 53:519–526CrossRefGoogle Scholar
- 49.Nakagawa H, Fujita T, Kubo S, Tokiyoshi K, Yamada M, Kanayama T, Hagiwara Y, Nakanomyo H, Hiraoka M (1996) Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor. Cancer Chemother Pharmacol 37:317–326. https://doi.org/10.1007/s002800050391 CrossRefGoogle Scholar